Collegium Pharmaceutical, Inc. (NASDAQ: COLL) is a Healthcare company (Drug Manufacturers - Specialty & Generic) with a market capitalization of $794M. The Maz Rating grades it against the other companies in its sector.
Collegium Pharmaceutical, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $25.55, Collegium Pharmaceutical, Inc. trades at 20.9x trailing earnings, 1.0x sales and 2.7x book value, with an EV/EBITDA of 4.5. Over the last twelve months it generated about $819M of revenue and $38M of net income. It runs a gross margin of 59.0%, an operating margin of 14.8% and a net margin of 4.7%. It shows return on equity of 12.5%, return on invested capital of 7.0% and a free cash flow yield of 42.4%. On the balance sheet: a debt-to-equity ratio of 3.67 and a current ratio of 1.01. Over the past 52 weeks the share price ranged from $21.43 to $50.79, with a beta of 0.73.
Collegium Pharmaceutical, Inc. does not currently pay a dividend.
12 Wall Street analyst ratings cover the stock: 8 Buy, 3 Hold and 1 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Collegium Pharmaceutical, Inc. (COLL) is a specialized pharmaceutical firm dedicated to the development and marketing of medications for pain management. Its diverse product lineup features significant therapies aimed at addressing various pain conditions. A prominent offering is Xtampza ER, an extended-release, oral formulation of oxycodone, specifically engineered with properties to deter abuse. This particular drug is prescribed for patients experiencing severe, persistent pain that necessitates daily, continuous, long-term opioid therapy. The company's portfolio also encompasses Nucynta ER and Nucynta IR, which are extended-release and immediate-release versions of tapentadol, respectively. Founded in 2002, the enterprise initially operated under the name Collegium Pharmaceuticals, Inc., before officially adopting its current identity as Collegium Pharmaceutical, Inc. in October 2003. The company's corporate headquarters are situated in Stoughton, Massachusetts.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Collegium Pharmaceutical, Inc. (COLL) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 140.3% / 30% · (Cash+Inv) / Mkt Cap (36m) 18.8% / 30% · Interest income / Revenue 0.52% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 140.3% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 18.8% / 33% · Receivables / Mkt Cap (36m) 40.3% / 49% · Interest income / Revenue 0.52% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 140.3% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 18.8% / 33.33% · Receivables / Mkt Cap (24m) 40.3% / 33.33% · Interest income / Revenue 0.52% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 48.8% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 14.6% / 33.33% · Receivables / Avg Assets (4Q) 13.7% / 33.33% · Interest income / Revenue 0.52% / 5% | Fail |
| FTSE | Debt / Total Assets 51.6% / 33.33% · (Cash+ST Inv) / Total Assets 6.91% / 33.33% · (Cash+Recv) / Total Assets 21.7% / 33.33% · Interest income / Revenue 0.52% / 5% | Fail |
No. As of September 2026, Collegium Pharmaceutical, Inc. (COLL) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Collegium Pharmaceutical, Inc. is over the AAOIFI limit on Debt / Mkt Cap (36m).
About 0.52% of each dividend: Collegium Pharmaceutical, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.